Amivantamab has demonstrated clinically meaningful activity in EGFR ex20ins NSCLC–showing an objective response rate of approximately 40% with a median duration of response of about 11 months as monotherapy in CHRYSALIS, and a statistically significant PFS benefit in the first-line PAPILLON trial when combined with platinum-pemetrexed (median PFS 11.4 vs. 6.7 months; HR 0.40) (8, 18). This evidence concerns the gene EGFR and non-small cell lung carcinoma.